We are studying how mepolizumab affects the nasal microbiome and immune response in patients with eGPA. This research may help understand its impact on local inflammation in the ENT area.
Health conditions and diseases that the clinical trial is designed to study and treat.
Eosinophilic Granulomatosis with Polyangiitis (eGPA) is a rare autoimmune disease that causes inflammation of blood vessels, leading to symptoms such as asthma, sinusitis, and skin rashes, often associated with high levels of eosinophils in the blood.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.